University of Hawai'i John A. Burns School of Medicine, Honolulu, HI, USA.
University of Hawai'i Pathology Residency Program, Honolulu, HI, USA.
Oncologist. 2023 Feb 8;28(2):116-122. doi: 10.1093/oncolo/oyac239.
Tumor-infiltrating lymphocytes (TILs) have emerged as a predictor of breast cancer treatment response and patient outcomes. Current studies investigating racial/ethnic differences in TILs and immune profiles in breast cancer offer varying results. Our study provides some preliminary data in the breast cancer tumor microenvironment where there is a paucity of information, from Asian and Native Hawaiian/Pacific Islander (NHPI) racial/ethnic groups, not well represented in the literature.
We reviewed 183 cases of women diagnosed with early stage breast cancer who received neoadjuvant treatment at 2 large health systems in Hawaii between 2008 and 2020. We evaluated clinical and demographic information including: age at diagnosis, self-reported race/ethnicity, tumor stage, tumor subtype according to ER, PR, and HER2 receptor status, the amount of TILs and pathologic complete response (pCR).
We found a significantly greater amount of TILs in Asians (37.7%, P = .01) and NHPI (37.2%, P = .02) patients compared to White patients on multivariate analysis. We found no significant differences in pCR among the different racial/ethnic groups.
Racial/ethnic differences in the amount of TILs in breast cancer tumors may suggest differences in the breast tumor microenvironment. This may in part contribute to known outcome disparities in these populations and should be further evaluated.
肿瘤浸润淋巴细胞(TILs)已成为预测乳腺癌治疗反应和患者预后的指标。目前的研究调查了乳腺癌中 TILs 和免疫特征的种族/民族差异,结果不一。我们的研究提供了一些初步数据,涉及亚洲和夏威夷原住民/太平洋岛民(NHPI)种族/民族群体的乳腺癌肿瘤微环境,这些群体在文献中代表性不足。
我们回顾了 2008 年至 2020 年间在夏威夷的 2 个大型医疗系统接受新辅助治疗的 183 例早期乳腺癌女性患者的病例。我们评估了临床和人口统计学信息,包括:诊断时的年龄、自我报告的种族/民族、肿瘤分期、根据雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体 2(HER2)受体状态的肿瘤亚型、TILs 数量和病理完全缓解(pCR)。
我们发现,在多变量分析中,亚洲(37.7%,P =.01)和 NHPI(37.2%,P =.02)患者的 TILs 数量明显多于白人患者。我们在不同种族/民族群体之间未发现 pCR 存在显著差异。
乳腺癌肿瘤中 TILs 数量的种族/民族差异可能表明乳腺癌肿瘤微环境存在差异。这可能部分导致了这些人群中已知的结局差异,应进一步评估。